Halozyme Therapeutics (HALO) Interest Coverage Ratio (2011 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Interest Coverage Ratio of 33.5 for Q1 2026, up 7.1% year-over-year from 31.28 in Q1 2025, and up 277.11% quarter-over-quarter from 18.91 in Q4 2025.
Halozyme Therapeutics (HALO) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Interest Coverage Ratio for 15 consecutive years, with 33.5 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 7.1% year-over-year to 33.5; the TTM figure through Mar 2026 stood at 26.48 (down 19.74% YoY), while the FY2025 annual figure was 25.87, down 15.1% from the prior year.
- Interest Coverage Ratio climbed to 33.5 in Q1 2026 per HALO's latest filing, from 18.91 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 46.07 in Q2 2025 and bottomed at 18.91 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 20.28 across 5 years, with a median of 21.02 in 2023.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio soared 262.88% — and 2025, when it plunged 148.93%.
- Halozyme Therapeutics' Interest Coverage Ratio stood at 11.88 in 2022, then jumped by 262.88% to 19.36 in 2023, then soared by 99.72% to 38.66 in 2024, then slumped by 148.93% to 18.91 in 2025, then jumped by 277.11% to 33.5 in 2026.
- Business Quant data shows HALO's Interest Coverage Ratio at 33.5 in Q1 2026, 18.91 in Q4 2025, and 6.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 48.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.75 |
| Mar 31, 2026 | 33.50 |
| Dec 31, 2025 | -18.91 |
| Sep 30, 2025 | 6.00 |
| Jun 30, 2025 | 46.07 |
| Mar 31, 2025 | 31.28 |
| Dec 31, 2024 | 38.66 |
| Sep 30, 2024 | 36.07 |
| Jun 30, 2024 | 25.91 |
| Mar 31, 2024 | 21.20 |
| Dec 31, 2023 | 19.36 |
| Sep 30, 2023 | 19.60 |
| Jun 30, 2023 | 21.02 |
| Mar 31, 2023 | 11.84 |
| Dec 31, 2022 | -11.88 |
| Sep 30, 2022 | 11.08 |
| Jun 30, 2022 | 10.97 |
| Mar 31, 2022 | 43.02 |
| Dec 31, 2021 | 27.51 |
| Sep 30, 2021 | 43.09 |